Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
5 lug 2015 ·
2 min. 57 sec.
![Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/42e5e18ddb21d203ac8e661da38f5929.jpg)
Scarica e ascolta ovunque
Scarica i tuoi episodi preferiti e goditi l'ascolto, ovunque tu sia! Iscriviti o accedi ora per ascoltare offline.
Descrizione
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can...
mostra di più
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
mostra meno
Informazioni
Autore | cancerGRACE |
Sito | - |
Tag |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company